The startup ARLAN BIOTECH from Kazakhstan has attracted investments from Mercury Software GmbH

Mercury Software GmbH has become an investor in ARLAN BIOTECH, a company that is changing the future of biotechnology through generative AI.

The founders of ARLAN BIOTECH first met with the Mercury Software GmbH team at StartX Demo Day. What began as a project presentation quickly evolved into a strategic partnership based on a shared vision for the future of technology in antibody discovery.

Co-founder Bolat Sultankulov, together with Daucken Seitkali, highlighted the significance of this partnership and the StartX network, which helped establish key connections.

ARLAN BIOTECH is developing an AI-based platform that accelerates the creation of highly accurate antibodies, and this investment round is considered an important step in scaling and validating the technology.

The Mercury Software GmbH team expressed confidence in the company's mission and innovative approach. ARLAN BIOTECH has a clear vision and strong founders who are capable of solving real-world challenges in biotechnology.

Source: LinkedIn